Your browser doesn't support javascript.
loading
Evaluation of Mogroside V as a Promising Carrier in Drug Delivery: Improving the Bioavailability and Liver Distribution of Silybin.
Luo, Yuqin; Gong, Chunyan; Wei, Mingmin; Chen, Yi; Song, Ting; Wu, Chunyong; Mo, Liying; Zhang, Junying.
Afiliação
  • Luo Y; Department of TCMs Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
  • Gong C; Department of Pharmacy, Hospital for Skin Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, 210042, Jiangsu, China.
  • Wei M; Department of TCMs Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
  • Chen Y; Department of TCMs Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
  • Song T; Department of TCMs Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
  • Wu C; Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China.
  • Mo L; Department of TCMs Pharmaceuticals, China Pharmaceutical University, Nanjing, 210009, Jiangsu, China. 841341223@qq.com.
  • Zhang J; , Nanjing, People's Republic of China. 841341223@qq.com.
AAPS PharmSciTech ; 21(4): 123, 2020 Apr 26.
Article em En | MEDLINE | ID: mdl-32337654
ABSTRACT
The objective of this work was to investigate the capacity of mogroside V (MOG-V), a food additive, as a novel carrier to improve the bioavailability and liver distribution of silybin (SLY). Solid dispersion particles (SDPs) of SLY/MOG-V were prepared utilizing the solvent evaporation method. The physicochemical characterizations of SDPs were evaluated by using dynamic light scattering (DLS), differential scanning calorimetry (DSC), and powder X-ray diffraction (PXRD) measurements. DLS results demonstrated the formation of nanoparticles (206 nm) of SDPs in water. DSC and PXRD analysis revealed that SLY was in amorphous form or molecularly dispersed in SDPs. SDPs also exhibited a major increase in both dissolution rate and saturation solubility, as evidenced by a 1931-fold improvement (2201 µg/mL) in solubility compared with pure SLY (1.14 µg/mL). The pharmacokinetic study in rats showed that oral absorption of SLY/MOG-V SDPs was dramatically increased. The mean value of AUC until 12 h for SLY/MOG-V SDPs (27,481 ng·min/mL) was 24.5-fold higher than that of pure SLY (1122 ng·min/mL). In vivo tissue distribution experiment in mice confirmed that the major distribution tissue was changed from lungs to liver after SLY was loaded into MOG-V. In addition, even orally administrated to mice at a high dose (4.2 g/kg), MOG-V exhibited no undesirable effect on the plasma glucose concentrations. Thus, MOG-V may have the applicability to serve as an ideal excipient for solubilization or as a novel liver targeting carrier for the delivery of SLY.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triterpenos / Portadores de Fármacos / Sistemas de Liberação de Medicamentos / Silibina / Fígado Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Triterpenos / Portadores de Fármacos / Sistemas de Liberação de Medicamentos / Silibina / Fígado Idioma: En Ano de publicação: 2020 Tipo de documento: Article